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The past 30 years have only seen slight improvement in melanoma therapy. Despite a wide variety of therapeutic options,
current survival for patients with metastatic disease is only 6–8 months. Part of the reason for this treatment failure is the broad
chemoresistance of melanoma, which is due to an altered survival capacity and an inactivation of apoptotic pathways. Several
targetable pathways, responsible for this survival/apoptosis resistance in melanoma, have been described and current research has
focused on mechanism inactivating these pathways. As PPARγ was shown to be constitutively active in several tumour entities
and PPARγ agonists extent strong anticancer eﬀects, the role of PPARγ as a possible target for speciﬁc anticancer strategy was
investigatedinnumerousstudies.However,onlyafewstudieshavefocusedontheeﬀectsofPPARγ agonistsinmelanoma,showing
conﬂicting results. The use of PPARγ agonists in melanoma therapy has to be carefully weighted against considerable, undesirable
side eﬀects, as their mode of action is not fully understood and even pro-proliferative eﬀects have been described. In the current
review, we discuss the role of PPARs,in particular PPARγ in melanoma and their potential role as a molecular target for melanoma
therapy.
Copyright © 2008 Christian Freudlsperger et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. MALIGNANT MELANOMA AND MOLECULAR
TARGETS IN MELANOMA THERAPY
Cutaneous malignant melanoma is the most aggressive form
of skin cancer. Despite attempts to treat melanoma using
a large variety of therapies, including immuno-, radio,
and chemotherapies, survival remains very poor once the
disease has spread to distant sites (median survival: 6–8
months) [1]. Systemic therapy, immunotherapy, or even
biochemotherapy have failed to improve the survival of
these patients. Until now, the only drug approved by the
FDA for treatment of metastatic melanoma is the alkylating
agent dacrabazine (DTIC), which results in clinical response
only of 5–10% of cases when given as a single agent
[2]. This treatment failure is mainly due to the notorious
chemoresistance of melanoma cells. In contrast to other
cancer cells, this chemoresistance of melanoma cells seems
not to be acquired selectively following drug therapy, but to
be more intrinsic in melanoma cells. Alteration of survival
capacity and inactivation of apoptotic pathways are the
molecular mechanisms responsible of conventional drug
resistance in melanoma cells (see Figure 1). One example
for a targetable pathway is the mitogen-activated protein
kinase (MAP-kinase) pathway, which plays a crucial role in
cell proliferation, invasion, and enhanced survival in diverse
cancers [3]. A key player in the MAP-kinase pathway is B-
RAF, a serin/threonine protein kinase acting as an oncogene
[4]. The recent identiﬁcation of activating mutations in B-
RAF in over 60% cases of melanoma has oﬀered the ﬁrst
opportunity for a rationale treatment program [3]a n de a r l y
clinical trials using the RAF kinase inhibitor BAY 43-9006
have been encouraging, being the ﬁrst positive example of
how targeted therapy can work in malignant melanoma.
Other examples of targetable pathways in melanoma are
the phosphoinositide-3-kinase (PI3K)/Akt pathway, which
can be activated either through growth factors or loss of
negative regulators of this pathway [5]. One of the most
critical regulators of Akt (also known as protein kinase B)
is the phophatase and tensin homologue (PTEN), which
degrades the products of PI3K, preventing the activation
of Akt [6]. In several studies it has been shown that up to
30% of melanoma, cell lines have lost PTEN expression [7].2 PPAR Research
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Figure 1:Activatingpathwaysknowntobeconstitutivelyactiveand
contributing to the chemoresistance of melanoma cells. Over 60%
of melanomas have activating mutations of B-RAF, 30% have lost
PTEN expression, majority with NF-κB activation.
Finally, Huang et al. investigated that the NFκ-B signaling
pathway, acting as a key regulator of survival in cancer
cells, is constitutively activated in melanoma cells [8]. In
addition, a recent study has demonstrated that inhibiting
NFκ-B activity, using the proteasome inhibitor bortezomib,
reduced melanoma cell growth in vitro [9]. Although these
targets seem to be attractive ones for melanoma therapy in
the future, most of the ﬁndings in this area do not give
a comprehensive picture which would warrant a review.
As several studies have shown an antiproliferative eﬀect
of PPARγ agonists on several tumour entities including
melanoma, this review focuses on the role of the PPARγ as
a possible target in melanoma therapy.
2. PPARγ AND PPARγ AGONISTS
The peroxisome proliferator-activated receptors (PPARs)
are ligand-activated transcription factors, belonging to the
nuclear receptor superfamily [10]. Activated PPAR forms
complexes with the retinoid receptor, which bind as a
heterodimer to peroxisome proliferator response elements
(PPREs) on the DNA, initiating transcription of down-
streamgenes.ThePPARsubfamilycomprisesthreeisoforms,
PPARα,P P A R β/δ,a n dP P A R γ, each showing a distinct
distribution and ligand preference. While PPARα is predom-
inantlyexpressedinmetabolicallyactivetissue,likeliver,kid-
ney, skeletal muscle and brown fat [11], PPARδ is expressed
ubiquitously. PPARγ is highly expressed in adipocytes, where
it functions as a key regulator of adipocyte diﬀerentia-
tion [12] and insulin-dependent glucose utilization [13].
Prostaglandin15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2)
is the most potent naturally occurring ligand for PPARγ
and the thiazolindinedione (TZD), also called glitazones, a
class of antidiabetic, insulin-sensitizing drugs, are speciﬁc
exogenous ligands for PPARγ. The TZD family of PPARγ
agonists includes rosiglitazone, pioglitazone, ciglitazone, and
troglitazone, rosiglitazone being the most potent agonist
(Kd = 40nM). In general, TZDs are selective for PPARγ in
concentrations of 10μMo rl e s s[ 14]. Recently, expression
of PPARγ has been demonstrated in tumor cells originating
from various malignancies, including breast, colon, lung,
gastric, pancreatic, prostate, and bladder cancer and its
activation through PPARγ agonists led to a signiﬁcant
decrease in proliferation of tumor cells in vitro [15–21],
however, the exact mecahnisms underlying this eﬀect are
still being explored. As a consequence, PPARγ has become a
molecular target for potential anticancer drug development.
3. PPARγ AND MELANOCYTES
Until now, there is little information on the PPAR subtypes
a n dr e l a t i v el e v e l so fP P A Rp r o t e i ne x p r e s s e di nh u m a n
skin. The three PPAR subtypes have been investigated in
human keratinocytes [22], and PPARγ ligands have been
shown to induce the expression of genes associated with
keratinocyte diﬀerentiation in vitro [23]. In addition, Kang
et al. showed the expression of all three PPAR subtypes
in human melanocytes [24]. Immunocytochemistry showed
that PPAR staining was mostly conﬁned to the cytoplasm.
Furthermore, proliferation of melanocytes was inhibited
through administration of PPARα (WY-14643) and PPARγ
(ciglitazone)agonistsbutnotthroughPPARβ/δ (bezaﬁbrate)
agonists in a dose dependent manner at concentrations
ranging between 0 and 100μM. The inhibitory eﬀect of
ciglitazone seemed to occur through induction of apoptosis,
which was observed by the TUNEL method and ﬂow cytom-
etry [25]. Moreover, Lee et al. showed that pigmentation
in melanocytes was accelerated with PPARα and PPARγ
agonists, suggesting a possible role for PPARα and PPARγ
in modulating melanocyte proliferation and diﬀerentiation
(pigmentation) [26]. Eastham et al. investigated the expres-
sion of mRNA for PPARα,P P A R β/δ,a n dP P A R γ in human
melanocytes [27]. In addition, the natural PPARγ agonist
15d-PGJ2 and the synthetic PPARγ agonists ciglitazone and
troglitazoneinhibitedthecellgrowthofhumanmelanocytes,
whereas the PPARα agonists WY14643 and Leukotriene B4
had no eﬀect on the proliferation of human melanocytes.
4. PPARγ AND MELANOMA CELLS
Only a few studies have focussed on PPARγ expression and
eﬀects of PPARγ agonists in melanoma cell lines (summa-
rizedinTable 1).M¨ ossneretal.investigatedtheexpressionof
PPARγ in four human melanoma cell lines MM-358, MM-
201, MM-254 (established from lymph node metastasis of
cutaneous malignant melanoma), and KAII (derived from
a cutaneous nodular melanoma) [29]. In accordance with
the immunocytochemistry of the melanocytes, staining was
predominantly localized in the cytoplasm. In addition, the
PPARγ agonists 15d-PGJ2, troglitazone, and rosiglitazone
dose-dependently inhibited the cell proliferation of all
melanoma cells at concentrations between 0 and 50μM. As
shown by ﬂow cytometry, this antiproliferative eﬀect was
not mediated through induction of apoptosis, but ratherChristian Freudlsperger et al. 3
Table 1: Eﬀects of PPARγ agonists on melanoma cell growth.
Cell line PPARγ agonist Concentration Results Mechanism of action Reference
UISO-Mel6, Rosiglitazone,
0.3–300μM
– Growth inhibition
o fa l lc e l ll i n e sa t
– Independent from apoptosis Freudlsperger et al.
[28]
MV3, MeWo, pioglitazone, 30–300μM,
G361, ciglitazone, – increase in cell
proliferation at
Lox troglitazone 3μM
MM-358, 15d-PGJ2,
0.1–50μM
– Growth inhibtion of
a l lc e l ll i n e sa t
20–50μM
– Independent from apoptosis,
M¨ ossner et al. [29] MM-201, troglitazone, – induction of G1 phase
MM-254, KAII rosiglitazone cell cycle arrest
SK-mel28, A375
Ciglitazone,
0–10μM
– Growth inhbition
only of A375 at
10μM
– Not investigated Eastham et al. [27] troglitazone,
15d-PGJ2
WM35, A375 Ciglitazone, 10–15μM
– Growth inhibition
o fa l lc e l ll i n e sa t – Induction of apoptosis Placha et al. [30]
15d-PGJ2 10–15μM
A375
Ciglitazone,
0–32μM
– Growth inhibtion
of A375 at 16μMo f
15d-PGJ2
– Induction of apoptosis
N´ u˜ nez et al. [31]
15d-PGJ2,
–n og r o w t h
inhibition by
ciglitazone
by induction of G1 phase cell cycle arrest. Eastham et al.
investigated the expressions of PPARα,P P A R β/δ,a n dP P A R γ
in human melanoma cells SK-mel28 and A375 [27]. Both
melanoma cell lines express PPARα protein levels 20–47%
higherandPPARγ proteinlevels40–50%higher,respectively,
thanthenormalhumanmelanocytes.However,mRNAlevels
and protein levels for these receptors did not match. In
addition, the natural PPARγ agonist 15d-PGJ2 and the syn-
thetic PPARγ agonists ciglitazone and troglitazone inhibited
the cell growth of the human melanoma cell line A375
in concentrations of 0–10μM, whereas the SK-mel28 cells
were not aﬀected in this concentration range. The PPARα
agonists WY14643 and leukotriene B4 had no eﬀect on the
cell proliferation of both cell lines. Placha et al. investigated
PPARγ expressioninthemelanomacelllinesWM35,derived
from a primary tumour site, and A375, derived from a solid
metastatic tumour. Furthermore, an antiproliferative eﬀect
of the PPARγ agonist ciglitazone and 15d-PGJ2 in both
melanoma cell lines was observed in concentrations of 10–
15μM[ 30]. The antiproliferative eﬀect of ciglitazone was
mediated through induction of apoptosis, as evidenced by
ﬂuorescence microscopy. N´ u˜ nez et al. showed an antiprolif-
erative eﬀect of 15d-PGJ2 on the melanoma cell line A375
at concentration of 16μM or higher, which was mediated
through induction of apoptosis, while ciglitazone showed
no growth inhibitory eﬀect [31]. Our own results showed
expression of PPARγ in six diﬀerent human melanoma
cells MV3, Lox, MeWo, G361, FemX-1, and UISO-Mel6,
which were established from primary malignant melanoma
or metastatic melanoma lymph node [28]. Similar to the
ﬁndings of M¨ ossner et al., immunocytochemical staining
of PPARγ was mostly conﬁned to the cytoplasm. The
PPARγ agonists rosiglitazone, pioglitazone, troglitazone, and
ciglitazone all showed a dose-dependent antiproliferative
eﬀect on all melanoma cell lines tested at concentrations of
30μM or higher. This antiproliferative eﬀect was due to a
mechanism independent from apoptosis, which was shown
by assessment of the nuclear morphology or by molecular
analysis of DNA fragmentation. Interestingly, all four PPARγ
agonists showed an increase in cell proliferation of all six
melanoma cell lines at concentrations of 3μM.
5. PPARγ-DEPENDENT OR -INDEPENDENT EFFECTS
OF PPARγ AGONISTS IN MELANOMA CELLS
Several studies have documented various mechanisms for
the antiproliferate eﬀect of PPARγ agonists, both being
dependent or independent of PPARγ activation, which holds
also true for melanoma cells. Using a reporter gene assay,
Eastham et al. showed that the PPARγ agonists 15d-PGJ2
and ciglitazone stimulated PPRE reporter gene activity in a
dose-dependentmannerinB16melanomacells.Thisactivity
correlated with their ability to inhibit cell proliferation,
hence a PPARγ-dependent mechanism was postulated [27].
Simularely, Placha et al. investigated, that the apoptosis
inducing eﬀect of ciglitazone in human melanoma cells was
clearly associated with the strong induction of transcription
by endogenous PPARγ through PPRE target sequences, as
shown in the reporter gene assay system [30]. On the
other hand, PPAR agonists have been reported to have
nonreceptor mediated eﬀects too. In our own studies, quan-
titative analyses of PPARγ protein showed no correlation
between the amount of the PPARγ protein and the respective
susceptibility of the melanoma cell lines towards PPARγ4 PPAR Research
agonists. Therefore, a PPARγ-independent eﬀect of PPAR-γ
agonists was assumed [28]. In other cancer cells, resistance
pathways which are constitutively activated in melanoma
cells (Figure 1)w e r ea ﬀected through PPARγ agonist inde-
pendent from PPARγ activation. For example, 15d-PGJ2 has
been shown to alter NF-κB activity in hepatocellular carci-
noma cells where 15d-PGJ2 induces apoptosis via caspase-
dependent and -independent pathways [32]. In addition,
Straus et al. showed a PPARγ-independent repression of
NF-κB by 15d-PGJ2 through two mechanisms, inhibition
of IκB kinase (IKK) and inhibition of NF-κB DNA binding
[33]. The inhibition of NF-κBb yP P A R γ agonists through
PPARγ-independent mechanisms could be a possible way
for the antiproliferative eﬀect in melanoma cells, especially
for the combination of the PPARγ agonist rosiglitazone with
bortzezomib, a potent inhibitor of NF-κB, has led to an
augmented antiproliferative eﬀect on melanoma cells [34].
In addition, Han and Roman investigated that rosiglitazone
inhibited the cell growth of human lung carcinoma cells
through inactivation of PI3K/Akt pathway and increase of
PTEN expression [35]. These changes were inhbited by
GW9662, a potent antagonist of PPARγ, suggesting that they
depend upon PPARγ activation. If this inactivation of the
PI3K/Akt pathway by rosiglitazone also contributes to the
antiproliferativeeﬀectofPPARγ agonistsinmelanomaneeds
to be further elucidated.
6. CONCLUSION
The rapid increase in incidence of malignant melanoma has
not been accompanied by better therapeutic options [36].
Thepastfewyearshaveseengreatleapsinourunderstanding
of the mechanism of drug resistance and cell survival in
melanoma. Many reports have indicated the central role of
PPARγ in the control of malignant cell growth in various
tumour entities including melanoma. In addition, evidence
has been accumulated that PPARγ is expressed in human
melanoma cells and that PPARγ speciﬁc agonists dose-
dependently inhibited proliferation of melanoma cells [27–
31]. However, these studies are inconsistent regarding the
concentration of PPARγ agonists initiating an antiprolif-
erative eﬀect and the mechanism underlying these growth
inhibitoryeﬀects.IncontrasttoPPARγ,PP ARαagonistswere
not shown to have antiproliferative eﬀects on melanoma
cells. Signiﬁcant inhibition of melanoma cell proliferation
did not occur until 20μM or higher concentrations of
PPARγ ligands were used. However, many natural and
synthetic PPARγ ligands loose their receptor selectivity at
these concentrations [37]. Furthermore, conﬂicting evidence
exists on the ability of PPARγ agonists to promote tumour
growth, depending on the cell model. For example, the
PPAR-γ agonist troglitazone increased cell proliferation of
breast cancer cells in low concentrations (<5μM), while
higher concentrations of troglitazone (100μM) inhibited cell
growth [38]. These investigations corroborate our published
data in melanoma cells. The PPARγ agonists rosiglita-
zone, troglitazone, pioglitazone, and ciglitazone showed an
increase in cell proliferation of all six melanoma cell lines
tested in low concentrations (3μM), however, in higher con-
centrations (>30μM) a signiﬁcant growth-inhibitory eﬀect
was observerd [28]. In addition, Lucarelli et al. reported that
troglitazone promoted the survival of osteosarcoma cells at
concentrations of 5μM, through the activation of the PI3-
kinase/Akt survival pathway (see Figure 1)[ 39]. Therefore,
the administered dose of PPAR-γ ligands in clinical trials
for melanoma therapy needs to be carefully deﬁned and
monitored closely.
In conclusion, the current studies concerning the role of
PPARγ in melanoma proliferation and progression report
conﬂicting results. The concentrations inducing growth
inhibitory eﬀects in melanoma cells seem to be diﬀerent
depending on the PPARγ agonist used and the melanoma
cellemployed.Inparticular,itremainstobefurtherexplored
whether activation of PPARγ itself or PPARγ-independent
eﬀects of PPARγ agonists contribute to the inhibition
of melanoma cell growth. Although the antiproliferative
eﬀect of PPARγ agonists in certain concentration ranges
in melanoma is undisputable, more detailed information
concerning the exact mechanisms seems to be necessary.
However, PPARγ might be a promising approach for target
speciﬁc anticancer strategy in the treatment of melanoma.
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